A Regulatory Inflection Point for Biologics – Will You Lead or React?
Written byNeta Kela, PhDFounder & Managing PartnerThe FDA's recent announcement signals a meaningful shift in how biologics and ultra-rare disease therapies may be evaluated — including openness to smaller, well-justified data packages when supported by strong scientific rationale.
This is not about lowering standards.
It's about smarter regulatory science.
For biologics-focused biotech companies, the implication is clear: regulatory strategy and CMC can no longer evolve in parallel tracks. Manufacturing decisions must reflect the regulatory logic from the very beginning.
For CDMOs, this is a strategic moment. Biotech companies will increasingly seek partners who understand development pathways, regulatory positioning, and long-term scalability — not just batch production.
Manufacturing is no longer downstream. It is part of the value creation story.
At Precise X Med, we work with EU biotech companies and manufacturing partners to integrate regulatory thinking, CMC strategy, and execution early — where it matters most.
How PXM Helps With This
IND-Enabling Regulatory Strategy
Pre-IND strategy, nonclinical package design, and IND readiness planning.
CMC Strategy & Manufacturing Readiness
CMC roadmaps, CDMO selection, comparability strategy, and CMC submissions.
PXM Webinars
Live sessions on FDA strategy, regulatory readiness, and pharma partnering.
Related
Part of FDA & CMC Readiness. Start from the pillar: Operate practice, FDA Regulatory Readiness, CMC & Manufacturing, FDA Expedited Pathways, EU Regulatory Pathways
What a Clinical Overview Must Contain for an EU Hybrid Application
What the Clinical Overview (Module 2.5) must cover in an EU hybrid application under Article 10(3), how to justify differences from the reference product, and where assessors push back.
Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
How to Choose an Independent Clinical Expert for Your EU Dossier
What Article 12 of Directive 2001/83/EC requires from the Clinical and Nonclinical Expert, what to look for when you appoint one, and the questions to ask before they sign.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.